Search Results

You are looking at 151 - 160 of 496 items for :

  • "adjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Tami Borneman, Barbara F. Piper, Virginia Chih-Yi Sun, Marianna Koczywas, Gwen Uman, and Betty Ferrell

N Courtens AM Abu-Saad HH Schouten HC . Fatigue in patients with breast cancer receiving adjuvant chemotherapy: a review of the literature . Cancer Nurs 2002 ; 25 : 283 – 297 ; quiz 298–299 . 15. Payne JK . The trajectory of fatigue

Full access

Peter E. Clark, Neeraj Agarwal, Matthew C. Biagioli, Mario A. Eisenberger, Richard E. Greenberg, Harry W. Herr, Brant A. Inman, Deborah A. Kuban, Timothy M. Kuzel, Subodh M. Lele, Jeff Michalski, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Jerome P. Richie, Wade J. Sexton, William U. Shipley, Eric J. Small, Philippe E. Spiess, Donald L. Trump, Geoffrey Wile, Timothy G. Wilson, Mary Dwyer, and Maria Ho

years, patients receiving CMV before surgery had a 16% reduction in mortality risk (hazard ratio, 0.84; 95% CI, 0.72–0.99; P =.037). Adjuvant Chemotherapy Data conflict regarding the role of adjuvant systemic chemotherapy in invasive bladder

Full access

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Brian Shuch, Kanishka Sircar, Brad Somer, Richard B. Wilder, Mary Dwyer, and Rashmi Kumar

associated with an increased risk of cancer and heart disease. However, if adjuvant chemotherapy is chosen, the NCCN Guidelines for Testicular Cancer recommend carboplatin AUC × 7 for either 1 or 2 cycles as a category 2A recommendation for patients with

Full access

Heidi Klepin, Supriya Mohile, and Arti Hurria

– 1717 . 33 Zauderer M Patil S Hurria A . Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer . Breast Cancer Res Treat 2008 ; in press . 34 Yancik R Wesley MN Ries LA . Effect of age

Full access

Mary F. Mulcahy, Andrew O. Wahl, and William Small Jr.

III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer . J Clin Oncol 2005 ; 23 ( suppl ): 1092S . 5 Tepper J Nardi G Sutt H . Carcinoma of the pancreas: review of MGH experience

Full access

Presenters: Alan P. Venook and Christopher G. Willett

,” wherein the patient undergoes long-course chemoradiotherapy (LCCRT) or short-course RT (SCRT) followed by surgery, then recovers to receive adjuvant chemotherapy. Due to some of the challenges with administering adjuvant chemotherapy in the postoperative

Full access

Tara M. Mackay, Lennart B. van Rijssen, Jurr O. Andriessen, Mustafa Suker, Geert-Jan Creemers, Ferry A. Eskens, Ignace H. de Hingh, Lonneke V. van de Poll-Franse, Mirjam A.G. Sprangers, Olivier R. Busch, Johanna W. Wilmink, Casper H. van Eijck, Marc G. Besselink, Hanneke W. van Laarhoven, and on behalf of the Dutch Pancreatic Cancer Group

postoperative clinical condition, adjuvant chemotherapy was offered. Palliative treatment was defined as any palliative systemic treatment of metastatic or locally advanced pancreatic or periampullary cancer. The start of treatment was defined as upfront surgery

Full access

Brian Badgwell

Syst Rev 2013 : CD008415 . 15. Earle CC Maroun JA . Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials . Eur J Cancer 1999 ; 35 : 1059 – 1064

Full access

Joleen M. Hubbard and Axel Grothey

older counterparts. Quah et al 11 found that 39% of patients aged 40 years or younger received adjuvant chemotherapy for stage II disease, compared with only 14% of older patients, even though the clinical and pathologic tumor characteristics were

Full access

Andrea Cercek, Karyn A. Goodman, Carla Hajj, Emily Weisberger, Neil H. Segal, Diane L. Reidy-Lagunes, Zsofia K. Stadler, Abraham J. Wu, Martin R. Weiser, Philip B. Paty, Jose G. Guillem, Garrett M. Nash, Larissa K. Temple, Julio Garcia-Aguilar, and Leonard B. Saltz

statistically significant rate of increased pathCR, or improvement in rates of failure-free or overall survivals, when comparing neoadjuvant chemotherapy followed by chemoradiotherapy and then surgery and adjuvant chemotherapy versus chemoradiotherapy followed